The following is a summary of “Association between the triglyceride-glucose index and liver fibrosis in adults with ...

Alentis Therapeutics ("Alentis"), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+ ...

Among the general US population, simple and affordable non-invasive liver fibrosis scoring systems may be able to identify individuals at risk for HF.

The tool’s performance was consistent across multiple validation cohorts, though accuracy varied slightly, especially when ...

The liver, serving as the body's natural filtration system, faces significant challenges from alcohol consumption. As this ...

SAN MATEO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company ...

In a series of studies at McMaster, Dr. Schertzer's research group demonstrated that treatment with QBECO SSI resulted in a ...

Hepatic fibrosis is the common result of injury to the liver from a variety of damaging mechanisms, and the accurate assessment of the degree of fibrosis is clinically important. For many years ...

The therapeutic candidate is under development for the treatment of liver fibrosis and KRAS-driven liver cancer. It is an antisense RNAi oligonucleotide delivered through lipid-nanoparticles and is ...

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously called non-alcoholic fatty liver disease, is a ...

MASH is a culmination of steatosis, inflammation, and fibrosis, and is also associated with comorbidities such as obesity and ...

Endoscopic sleeve gastroplasty combined with lifestyle changes was more effective for weight loss in patients with MASH and obesity than lifestyle changes alone.